Vivian Berlin

Executive Director, HMS

Displaying: 1 - 10 of 28 Results

Regenerative Cell Therapy for Skeletal Muscle Disorders

A startup emerging from Lee Rubin's lab aims to provide a long-term cell therapy regenerative solution for conditions that result in reduced or improper skeletal muscle regeneration. (Image credit: B.D. Colen/Harvard Staff.)Cell therapies hold…

Investigators

  • Lee L. Rubin

Polymixin synergistic novobiocin analogs for efficacious and safer treatment of Gram negative infections

The lipopolysaccharide (LPS) containing outer membrane of Gram-negative bacteria prevent penetration of antibiotics, making them ineffective against infections. Polymyxins, including colistin, bind LPS and disrupt the outer membrane and hence are…

Investigators

  • Daniel E. Kahne

New insightful biomarkers for ALS and dementia

About 90% of the amyotrophic lateral sclerosis (ALS) cases are seemingly “sporadic” without a family history of disease. With hundreds of distinct variants in more than a dozen genes contributing to disease risk, it is hard to identify disease…

Investigators

  • Kevin Carl Eggan

Stapled peptide that inhibits bacterial transporter

Multidrug-resistant infection has become a worldwide epidemic in recent years especially in hospitals and other community-associated settings, causing great suffering of patients and huge healthcare burden. According to CDC, at least 23,000 people…

Investigators

  • Martin Karplus

Method for large-scale production of differentiated neurons

INTRODUCTIONHuman pluripotent stem cells (hPSC’s) can be used to generate a wide variety of somatic cell types. In addition, they can be grown in large numbers and thus can be a tractable source for cell types that are otherwise difficult to…

Investigators

  • Lee L. Rubin

In vivo gene editing in dystrophic muscle

Duchenne Muscular Dystrophy (DMD) is a debilitating disease caused by the absence of dystrophin, a protein expressed in muscle fibers. This X-linked disease affects 1 in 3000/4000 male births and average life expectancy is 26. While improvements in…

Investigators

  • Amy Jo Wagers

Novel antibiotics against Gram-negative and drug-resistant bacterial pathogens

Dr. Kahne has a pipeline of programs aimed at developing first-in-class antibiotics:Program I: Potentiator of polymixin, increasing its therapeutic index for treatment of drug-resistant infectionsIn vitro: Novel agent potentiates activity of…

Investigators

  • Daniel E. Kahne

aP2 knock-out mice

AP2 knock-out mutant mice were developed by Dr. Gokhan Hotamisligil at Harvard Medical School (Science. 1996 Nov 22;274(5291):1377-9). AP2, also known as Fatty Acid-Binding Protein 4 (FABP4), encodes the adipocyte FABP. It plays important roles in…

Investigators

  • Gokhan S. Hotamisligil

KRT14-Cre mouse line

Hemizygous Tg(KRT14-cre)1Amc/J (also known as K14-Cre) transgenic mice were developed in the laboratory of Dr. Andrew P. McMahon at Harvard University. The mouse strain harbors Cre recombinase under the control of human keratin-14 promoter, which…

Investigators

  • Andrew P. McMahon

Ngn3-Cre transgenic mice for studying pancreatic development

Hemizygous transgenic Tg(Neurog3-cre/Esr1*)1Dam/J mice (also known as Ngn3/CreERTM) were developed in the laboratory of Dr. Douglas A. Melton at Harvard University. The mice contain a fusion protein of Cre recombinase and mutant mouse estrogen…

Investigators

  • Douglas Melton

Page 1 of 3